High-quality trials have demonstrated that mineralocorticoid receptor antagonists (MRA) including spironolactone and eplerenone reduce mortality and readmissions among patients with heart failure with a reduced ejection fraction (HFrEF) compared to placebo [2–5]. Here, NR3C2 is linked to heart failure.